Descripción de la empresa
Dyadic International, Inc. operates as a biotechnology platform company focused on the development, production, and sale of industrial enzymes and other proteins across the United States and international markets. Within the broader Healthcare sector, the company specifically functions in the Biotechnology industry, where it leverages its proprietary C1 platform to advance pharmaceutical applications and facilitate the production of pharmaceutical products. The entity currently holds a market capitalization of $32.05 million and generates annual revenue totaling $3.09 million, while specific employee headcount data is not disclosed in available records. These valuation and revenue figures indicate that Dyadic International is a small-cap entity operating with a limited revenue base relative to its market valuation, suggesting a high reliance on future product pipeline execution or strategic partnerships to justify its current market price relative to its financial outputs.
Salud financiera
The company reported revenue of $3.09 million over the trailing twelve months, yet it recorded a net income loss of $7,364,628, revealing a cost structure where expenses significantly outweigh revenue generation. This substantial gap between revenue and net income highlights the inherent high burn rate typical of early-stage biotechnology firms investing heavily in research and development. The firm generated negative free cash flow of $-4,524,691, which indicates a lack of financial flexibility and an ongoing requirement for external capital injections to sustain operations. Margin analysis shows a gross margin of 24.9%, suggesting moderate efficiency in production costs, while the operating margin stands at -269.6% and the profit margin at -238.3%, reflecting extreme operational inefficiencies driven by heavy overhead costs relative to sales. Regarding liquidity and leverage, the company holds $7.32 million in cash against $5.06 million in debt, resulting in a debt-to-equity ratio of 410.63, which characterizes a highly leveraged balance sheet despite the positive cash position. The current ratio is 2.68, indicating that the company possesses sufficient short-term assets to cover its short-term liabilities, providing a buffer against immediate liquidity pressures. Return on Equity is -397.8% and Return on Assets is -44.9%, metrics that reveal management has not yet been effective at generating positive returns on the capital invested by shareholders or deployed into assets.
Evaluación de valoración
Valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to the absence of positive net income and a forward P/E of -2.75, which implies that the market is pricing in expected future earnings recovery rather than current profitability. The price-to-book ratio is 25.87, indicating a significant market premium over the company's book value, a common characteristic for biotechnology firms where future intellectual property potential outweighs current asset valuations. Alternative valuation measures include a price-to-sales ratio of 10.37 and an EV/EBITDA metric listed as N/A, suggesting that analysts rely heavily on revenue multiples to assess the company's worth given its current lack of earnings. The stock price has fluctuated between a 52-week high of $1.35 and a 52-week low of $0.65; without a specific current price provided in the facts, the valuation range defines the volatility envelope within which the security has traded over the last year. The beta is 1.21, meaning the stock exhibits higher price volatility than the broader market, moving 21% more than the market index on average during periods of fluctuation.
Growth & Income
Revenue growth year-over-year stands at -30.8%, while earnings growth is N/A due to the absence of positive prior-year earnings for comparison, indicating a contraction in sales volume or pricing power. Since the company is not a dividend payer, with a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute income to shareholders but instead retains any potential earnings to fund operations and R&D. The company reinvests its limited earnings or existing cash reserves into growth initiatives rather than paying dividends, a strategy consistent with the lifecycle of a biotechnology platform company seeking product commercialization. The overall growth and income profile is defined by negative revenue expansion and zero dividend distribution, highlighting a capital-intensive phase focused on long-term pipeline development rather than immediate financial returns or income generation for investors.